The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of BEBT-209, a primary CDK4 inhibitor, in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer.
 
Quchang Ouyang
No Relationships to Disclose
 
Yongkui Lu
No Relationships to Disclose
 
Huihui Li
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Yunjiang Liu
No Relationships to Disclose
 
Tao Wu
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose
 
Jun Xiao
No Relationships to Disclose
 
Changgeng Qian
Employment - BeBetter Med, Inc
Leadership - BeBetter Med, Inc
Stock and Other Ownership Interests - BeBetter Med, Inc
Research Funding - BeBetter Med, Inc
Patents, Royalties, Other Intellectual Property - BeBetter Med, Inc
Travel, Accommodations, Expenses - BeBetter Med, Inc
 
Qiang Liu
No Relationships to Disclose